Patients treated with 1–2 prior NHAs and at most 1 prior chemotherapy regiment each for castration-sensitive prostate cancer and CRPC were divided into biomarker-defined subgroups: AR T878X/H875Y positive subgroup, wild-type AR or other AR mutations subgroup, AR L702H or AR-V7 alterations mutations subgroup where these two mutations are not degraded by ARV-110 (Gao X. et al., 2022). This evidence concerns the gene AR and Familial prostate cancer.